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SUMMARY (40 words or less): Universal antiretroviral treatment (ART) policies led to increases in rapid 
ART initiation among young adolescents, ages 10-14 years, after enrollment in HIV care.  Immediate 
increases in rapid ART initiation were observed after policy adoption in some countries. 
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ABSTRACT:  
 
Background: Young adolescents with perinatally-acquired HIV are at risk for poor care outcomes. We 
examined whether universal antiretroviral treatment (ART) eligibility policies (Treat All) improved rapid 
ART initiation following care enrollment among 10-14-year-olds in seven sub-Saharan African countries. 
 
Methods: Regression discontinuity analysis and data for 6,912 10-14-year-old patients were used to 
estimate changes in rapid ART initiation (within 30 days of care enrollment) following adoption of Treat 
All policies in two groups of countries: Uganda and Zambia (policy adopted in 2013) and Burundi, 
Democratic Republic of the Congo, Kenya, Malawi, and Rwanda (policy adopted in 2016).  
 
Results: There were immediate increases in rapid ART initiation among young adolescents after national 
adoption of Treat All. Increases were greater in countries adopting the policy in 2016, compared with 
those adopting it in 2013: 23.4 percentage points (pp) (95%CI: 13.9-32.8) vs. 11.2pp (95%CI: 2.5-19.9). 
However, the rate of increase in rapid ART initiation among 10-14-year-olds rose appreciably in 
countries with earlier treatment expansions, from 1.5pp per year before Treat All to 7.7pp afterwards.  
 
Conclusions: Universal ART eligibility has increased rapid treatment initiation among young adolescents 
enrolling in HIV care. Further research should assess their retention in care and viral suppression under 
Treat All. 
 
Keywords: adolescents, Treat All, ART eligibility, ART initiation, sub-Saharan Africa, regression 
discontinuity 
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INTRODUCTION  
 
In 2018, an estimated 599,000 young adolescents, ages 10 to 14 years, were living with HIV, with close 
to 90% in sub-Saharan Africa [1, 2]. While data on this age group are limited [3, 4], young adolescents 
living with HIV are presumed to have acquired HIV perinatally [5, 6]. Studies suggest that adolescents 
aged 10 to 14 may be less likely than younger children and older age groups to be tested for HIV 
because of slow-progressing disease, HIV-related stigma, parental concerns about disclosing their own 
status, and HIV testing strategies, including requirements for caregiver consent, that are not tailored 
towards adolescents [7-13].  
 
Disproportionately high HIV-related mortality rates have been reported for young adolescents, 
compared with older adolescents who likely acquire HIV later in life [2]. Young adolescents enrolling in 
HIV care are often underweight and stunted, and they tend to have lower CD4 counts and more 
advanced disease than both older adolescents [14, 15] and younger children diagnosed earlier following 
perinatal infection [16].  Research has shown that adolescents are also at greater risk of failing to initiate 
antiretroviral treatment (ART), particularly if they are ineligible for treatment at the time they enroll in 
HIV care [17]. The extent to which treatment eligibility guidelines have constrained ART initiation for 
adolescents is unknown. Before 2015, the World Health Organization (WHO) provided consolidated 
guidance on HIV treatment for both adolescents, ages 10 to 19 years, and adults that based ART 
initiation on CD4 count and clinical eligibility criteria [18-21]. Although a few countries in sub-Saharan 
Africa extended HIV treatment to all adolescents aged 15 or below in 2013 [22, 23], adolescents only 
became universally eligible for immediate treatment with the WHO’s 2015 recommendation to treat all 
people living with HIV/AIDS (PLHA), irrespective of immunologic or clinical status [18].  
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Using longitudinal patient data from seven countries participating in the International epidemiology 
Databases to Evaluate AIDS (IeDEA) research consortium, we assessed changes in rates of rapid ART 
initiation among 10-to-14-year-old patients newly enrolling in HIV care following national adoption of 
Treat All policies for young adolescents or Treat All policies for the general population of PLHA. 
 
METHODS  
 
Data sources and management 
Patient data: The IeDEA consortium (www.iedea.org) assembles sociodemographic and clinical data on 
adult and pediatric patients receiving HIV care across seven regional cohorts [24]. The data represent 
diverse clinical sites, the majority of which (87%) are public-sector health facilities, including primary 
(42%), as well as secondary and tertiary level sites (58%) [25]. In this analysis, we used medical records 
from 10-to-14-year-old patients newly enrolling in HIV care from 2010 to 2018 in seven sub-Saharan 
African countries in three IeDEA regions. These countries were selected because patient data were 
available for analysis following the adoption of universal treatment eligibility policies (Central Africa: 
Burundi, Democratic Republic of the Congo [DRC], and Rwanda; East Africa: Kenya and Uganda; 
Southern Africa: Malawi and Zambia). Prior to data analysis, each region’s data were standardized by 
regional data managers in accordance with IeDEA data definitions and formatting standards 
(iedeades.org).  
  
For each country, we identified the date when ART eligibility was first extended to all patients aged 10 
to 14 years, either as part of a pediatric (<15 years) Treat All policy, or a general Treat All policy 
(covering patients of all ages). If a country first adopted a pediatric Treat All policy and subsequently 
adopted a general Treat All policy, we recorded both dates. We have previously described our 
systematic search for current and historical ART eligibility guidelines based on publicly available policy 
D
ow
nloaded from
 https://academ
ic.oup.com
/jid/advance-article-abstract/doi/10.1093/infdis/jiz547/5612125 by U
niversitaetsbibliothek Bern user on 11 N
ovem
ber 2019
Ac
ce
pt
ed
 M
an
us
cr
ipt
 
7 
 
documents, published literature, and input from in-country experts [26]. If the exact day of expansion 
was unknown, it was assumed to have occurred on the first day of the month in which the policy was 
adopted.  
  
Data were de-identified before sharing and approved for use by local research ethics committees in 
each of the IeDEA regions included in the study. 
  
Inclusion criteria 
Patients: Patients had to be between 10 and 14 years of age at the time of enrollment into HIV care, 
with at least 30 days of possible follow-up between enrollment and database closure. Patients were 
excluded if they were known to have transferred to an IeDEA site from another clinic or were known to 
be ART-experienced at enrollment. 
Sites: Sites had to have patient data available for the period between care enrollment and ART initiation 
(i.e., pre-ART data) for both ART initiators and non-initiators (i.e., those dying or dropping out of care 
prior to starting treatment). Sites with data only from the period following ART initiation were excluded.  
  
Outcome and exposure 
The outcome of interest was “rapid” ART initiation, and was defined as initiation of treatment within 30 
days of enrollment in HIV care, which is consistent with our prior analyses in adults [27]. This definition 
differs from the 2017 WHO definition of rapid ART initiation, which is ART-initiation occurring within 
seven days of HIV diagnosis [28]. The exposure was period of enrollment in HIV care, as defined by the 
relationship to the calendar date of country-level ART eligibility expansion to Treat All. 
  
Other definitions 
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ART was defined as treatment with any regimen of at least three antiretroviral drugs, excluding 
antiretrovirals taken solely for the prevention of mother-to-child transmission. As a measure of HIV 
disease severity, pre-treatment CD4 count was defined as the CD4 closest to the enrollment date within 
a 90-day window (before or after), but no later than one week after ART initiation. 
  
Study design 
  
Descriptive analyses 
  
Patient characteristics, including sex, age, availability of pre-treatment CD4 measure, and median CD4, 
were described for each country where a pediatric or general Treat All policy extended ART eligibility to 
all children ages 10 to 14 years, and were aggregated by time period of policy change. The proportion of 
patients initiating ART rapidly in the year before and after Treat All adoption was calculated for each 
country and for the Central Africa region (i.e., Burundi, DRC, and Rwanda) because of small sample sizes 
available for the individual countries. 
  
Effect of ART eligibility expansion to Treat All on rapid ART initiation 
  
The effect of enrollment in HIV care under Treat All on the proportion of young adolescents initiating 
ART rapidly was assessed using a regression discontinuity design. This approach takes advantage of local 
randomness in a continuous eligibility assignment variable (calendar time of HIV care enrollment), 
relative to a cut-off threshold (date of country-level adoption of pediatric or general Treat All). In this 
quasi-experimental condition, as long as there is no evidence that values of the assignment variable are 
being manipulated, patients enrolling in care directly before and after the cut-off date are considered 
exchangeable. Accordingly, there should be no systematic differences in measured and unmeasured 
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characteristics between the groups, other than the higher probability of treatment eligibility among 
those enrolling after Treat All policy adoption. If these assumptions are met, observed effects can be 
interpreted causally, as intention-to-treat estimates [29, 30].  
 
To assess whether there were systematic differences between patients enrolling in HIV care on either 
side of the threshold, as well as non-random enrollment before or after the Treat All adoption date, we 
used covariate balance tests and plots of the date of enrollment in HIV care. As complete information 
about each patient’s true ART eligibility status at enrollment prior to Treat All adoption was not known 
(because of missing information on HIV stage, comorbidities, pregnancy, and/or special population 
status), the study is an intention-to-treat analysis using a “sharp” regression discontinuity design [29, 
30].  
  
We examined the association between calendar time of enrollment in HIV care and rapid ART initiation 
for two groups of countries: those where a pediatric Treat All policy extended ART eligibility to all 
children 10 to 14 years old in 2013, and those where a general Treat All policy extended ART eligibility to 
this age group along with adults in 2016. A discontinuity at the date of each country’s Treat All policy 
adoption allowed for different slopes before and after the cutoff, or threshold, date. Local linear 
regression models [31] were used to estimate predicted outcomes and risk differences at the Treat All 
threshold date as follows:  
𝐸[𝑌𝑖|𝑍𝑖] = 𝛽0 + 𝛽1 ∗ 𝑍𝑖 + 𝛽2 ∗ 1[𝑍𝑖 ≥ 0] + 𝛽3 ∗ 𝑍𝑖 ∗ 1[𝑍𝑖 ≥ 0] 
 
where Yi is the patient-level outcome (rapid ART initiation), Zi is the number of days between a patient’s 
enrollment date and national Treat All policy adoption date (negative if patient enrolled before the 
policy was adopted), and 1[Zi ≥ 0)] indicates whether a patient enrolled after the policy was adopted or 
not. 
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Data-driven Imbens-Kalyanaraman bandwidths [32] were used to define windows of time around the 
date of Treat All adoption within which predicted outcomes and risk differences at the Treat All 
threshold date were estimated. All observations within the bandwidth were weighted equally. 
Sensitivity analyses were completed using three other bandwidth sizes, ranging from 150 to 450 days.  
 
In the countries with a general Treat All expansion to all ages following a pediatric Treat All policy, an 
additional regression discontinuity analysis for the general Treat All adoption was completed to assess 
whether further expansions of eligibility criteria to encompass older age groups affected rapid ART 
initiation among already-eligible 10-to-14-year-olds. Such effects could be positive (increase in rapid ART 
initiation because of, for example, stigma reduction) or negative (decrease in rapid ART initiation 
because of, for example, facility capacity constraints).  
  
Trends in rapid ART initiation before and after Treat All adoption 
 
To characterize trends in rapid ART initiation following enrollment into HIV care, slopes from linear 
regression models for the period before and after the date of Treat All adoption were compared, and 
expressed as percentage point change in rapid ART initiation per year (i.e., average annual rate of 
increase).  
 
Analyses were completed in SAS 9.4 and Stata/MP version 15.1. 
 
RESULTS  
 
Sample characteristics 
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Longitudinal data were available for 7,296 patients ages 10 to 14 years who enrolled in HIV care 
between 2010 and 2018, including 7,239 (99.2%) with at least 30 days of possible follow-up. Of these 
patients, 6,912 (95.5%) had no evidence of transfer from another site or ART prior to enrollment. 
 
Among the seven countries in the analysis, five (Burundi, DRC, Kenya, Malawi, Rwanda) adopted general 
Treat All policies that extended treatment eligibility to young adolescents ages 10 to 14 years in 2016. 
Two countries (Uganda, Zambia) adopted pediatric Treat All policies in 2013, which extended treatment 
to all children younger than 15 years, and adopted general Treat All policies in 2016. (Supplementary 
Table 1)  
 
Among the 6,912 patients who met study inclusion criteria, 3,592 (52.0%) were in countries where 
pediatric Treat All was adopted in 2013, and 3,320 (48.0%) in countries where general Treat All was 
adopted in 2016. The median age at enrollment in HIV care was 12 years (interquartile range [IQR]: 11-
13), with no significant age differences before and after Treat All adoption (Supplementary Table 2), and 
58.3% were female. The availability of pre-treatment CD4 count measures varied across countries and 
before vs. after Treat All policy adoption. Few patients had pre-treatment CD4 measures following the 
adoption of Treat All policies, particularly in countries that introduced the policy in 2016 (20.1% overall, 
and only 3% among patients from Malawi). Among patients with a pre-treatment CD4 count, the median 
value before Treat All adoption was 315 cells/µl (IQR: 124-551) in countries adopting general Treat All 
policies in 2016 and 363 cells/µl (IQR: 193-589) in countries that adopted a pediatric Treat All policy in 
2013 (Table 1). 
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Table 1. Characteristics of adolescents 10 to 14 years of age enrolling in HIV care (n=6,912), 2010-2018. 
  General Treat All adopted in 2016   Pediatric Treat All adopted in 2013 
  Burundi DRC Kenya Malawi Rwanda Overall   Uganda Zambia Overall 
Treat All adoption date Sep 2016 Sep 2016 Jul 2016 May 2016 Jul 2016 2016  Dec 2013 Dec 2013 2013 
Total enrollments (%) 178 (2.6%) 123 (1.8%) 1,752 (25.3%) 1,168 (16.9%) 99 (1.4%) 3,320 (48.0%)  461 (6.7%) 3,131 (45.3%) 3,592 (52.0%) 
Period of enrollment           
Before Treat All adoption 154 (86.5%) 110 (89.4%) 1548 (88.4%) 1067 (91.4%) 82 (82.8%) 2,961 (89.2%)  257 (55.7%) 1635 (52.2%) 1,892 (52.7%) 
After Treat All adoption 24 (13.5%) 13 (10.6%) 204 (11.6%) 101 (8.6%) 17 (17.2%) 359 (10.8%)  204 (44.3%) 1496 (47.8%) 1,700 (47.3%) 
Sex           
Male 73 (41.0%) 67 (54.5%) 702 (40.1%) 511 (43.8%) 50 (50.5%) 1,403 (42.3%)  186 (40.3%) 1294 (41.3%) 1,480 (41.2%) 
Female 105 (59.0%) 56 (45.5%) 1050 (59.9%) 657 (56.3%) 49 (49.5%) 1,917 (57.7%)  275 (59.7%) 1837 (58.7%) 2,112 (58.8%) 
Age (years)           
Median (IQR) 12 (11-13) 12 (11-13) 12 (11-13) 12 (11-13) 12 (11-13) 12 (11-13)  12 (11-13) 12 (11-13) 12 (11-13) 
Pre-treatment CD4 measure before Treat All adoption        
CD4 measure available 42 (27.3%) 79 (71.8%) 1,073 (69.3%) 235 (22.0%) 66 (80.5%) 1,495 (50.5%)  167 (65.0%) 1,090 (66.7%) 1,257 (66.4%) 
Median CD4 count 
(cells/µl) (IQR) 
417 (220-762) 297 (93-499) 315 (120-574) 308 (145-456) 400 (176-675) 315 (124-551)  377 (197-671) 359 (193-579) 363 (193-589) 
Pre-treatment CD4 measure after Treat All adoption         
CD4 measure available 5 (20.8%) 1 (7.7%) 53 (26.0%) 3 (3.0%) 10 (58.8%) 72 (20.1%)  106 (52.0%) 704 (47.1%) 1,700 (47.7%) 
Median CD4 count 
(cells/µl) (IQR) 
N/A N/A 397 (233-558) N/A N/A N/A  408 (194-579) 343 (173-545) 347 (173-554) 
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IQR = interquartile range;  DRC = Democratic Republic of the Congo
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Distributions of baseline characteristics among newly enrolling patients were similar just before and just 
after Treat All adoption (Supplementary Table 2). No major discontinuity in the number of new 
enrollments around the date of Treat All adoption was observed (Supplementary Figure 1). 
 
Figure 1. Proportions of adolescents 10 to 14 years old initiating ART rapidly (within 30 days of 
enrollment in HIV care) in the years before and after Treat All adoption, by country or region. 
 
Rapid ART initiation before and after Treat All adoption (descriptive analysis) 
 
There were appreciable increases in rapid ART initiation among young adolescents in the year following 
Treat All adoption in all seven countries. Increases ranged from 16.3 percentage points (pp) in Zambia 
(from 37.4% in the year before to 53.7% in the year after) to 33.7pp in Uganda (from 41.3% to 75.0%, 
respectively). The proportion of young adolescents rapidly initiating ART in the year after Treat All 
adoption was highest in Malawi and Kenya (88.1% and 86.5%, respectively), both of which adopted a 
general Treat All policy in 2016. (Figure 1). 
 
Effect of Treat All adoption on rapid ART initiation (regression discontinuity analysis) 
 
Statistically significant increases in rapid ART initiation among young adolescents were observed 
immediately after national Treat All policies expanded treatment eligibility for this age group. A larger 
absolute effect was observed in the group of countries that adopted a general Treat All policy in 2016 
(Burundi, DRC, Kenya, Malawi, Rwanda): 23.4pp (95% CI: 13.9, 32.8), compared with the countries with a 
2013 pediatric Treat All policy (Uganda, Zambia), where there was an 11.2pp increase in rapid ART 
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initiation (95% CI: 2.5, 19.9). In the 2016 Treat All group, 85.4% of young adolescents enrolling 
immediately after Treat All adoption initiated ART rapidly (up from 62.0% immediately before), while in 
the 2013 group, 50.2% of young adolescents initiated rapidly after the expansion (up from 39.0% 
immediately before; Table 2, Figure 2).  
 
Table 2. Effect of ART eligibility expansion to treat all adolescents 10 to 14 years old and trends in 
rapid ART initiation before and after Treat All adoption. 
Expansion date 2016 2013 2016 
Expansion type General Treat All Pediatric Treat All General Treat All 
Countries 
Burundi, DRC, 
Kenya, Malawi, 
Rwanda 
Uganda, Zambia Uganda, Zambia 
Risk difference at the Treat All adoption 
threshold* 23.4 11.2 -1.1 
95% CI 13.9 - 32.8 2.5 - 19.9 -13.9 - 11.7 
p-value <0.001 0.012 0.862 
Imbens-Kalyanaraman bandwidth, days 681 780 252 
N within bandwidth 970 1,937 665 
Predicted outcomes at the Treat All threshold*    
Enrollment just before Treat All adoption 62.0% 39.0% 77.7% 
Enrollment just after Treat All adoption 85.4% 50.2% 76.6% 
Relative change after Treat All adoption 37.7% 28.7% -1.4% 
Slopes before and after Treat All adoption**    
Percentage point change in rapid ART initiation 
per year before Treat All adoption 4.1 1.5 5.8 
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Percentage point change in rapid ART initiation 
per year after Treat All adoption 2.0 7.7 4.4 
P-value for difference of slopes 0.693 <0.001 0.928 
ART = antiretroviral treatment; DRC = Democratic Republic of the Congo 
*Risk difference and predicted outcomes at the Treat All threshold are from regression discontinuity analyses. 
Effects are calculated at the guideline expansion threshold of one day before versus one day after Treat All 
adoption. 
**Slope comparison is from separate linear regression models comparing the periods before Treat All adoption 
and after Treat All adoption. 
 
Figure 2. Trends in rapid ART initiation before and after Treat All adoption among adolescents 10 to 14 
years old, by year of Treat All adoption. 
 
There was no statistically significant change in rapid ART initiation among young adolescents 
immediately after general Treat All policies were adopted in Uganda and Zambia in 2016 (Table 2). 
Pediatric Treat All policies were already in place in these two countries, and the proportion of young 
adolescents initiating ART rapidly was 77.7% immediately before the general Treat All policy, versus 
76.6% immediately after.  
 
Results of sensitivity analyses using other bandwidths were consistent with the findings based on the 
data-driven Imbens-Kalyanaraman bandwidth (Supplementary Table 3). 
 
Trends in rapid ART initiation before and after Treat All adoption (slope comparison) 
 
The average annual rate of increase in rapid ART initiation among young adolescents rose in countries 
where a pediatric Treat All policy was adopted in 2013, from 1.5pp per year before Treat All adoption to 
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7.7pp afterwards (Table 2). However, no statistically significant change in the annual rate of increase in 
rapid ART initiation was observed in countries that adopted a general Treat All policy in 2016. In 
addition, no rate change was observed in Uganda and Zambia following the expansion of pediatric Treat 
All policies to include all PLHA in 2016.  
 
DISCUSSION 
 
Whether part of a pediatric Treat All policy or a general Treat All policy, expansions of HIV treatment 
eligibility to those under age 15 were followed by significant and substantial in reases in ART initiation 
among 10- to 14-year-olds within 30 days of enrollment in HIV care. Increases in rapid ART initiation 
were particularly large following national adoptions of a general Treat All policy (i.e., for all ages) in 2016 
in Burundi, DRC, Kenya, Malawi, and Rwanda. Observed increases in the proportion of young 
adolescents rapidly initiating ART following national adoption of Treat All policies may have substantial 
clinical importance, given evidence indicating that young adolescents with perinatally-acquired HIV 
often enroll in care late and do not initiate ART until they are at advanced stages of disease [14, 15, 33-
35].  
 
Pre-treatment CD4 measures were not available for a large proportion of patients, making it difficult to 
ascertain clinical eligibility for treatment among those enrolling before Treat All policies were adopted. 
However, among the 56.7% of young adolescents with pre-treatment CD4 data available prior to Treat 
All adoption, median CD4 counts for each country in our study were well below 500 cells/ul, the 
previous immunologic threshold for treatment eligibility. This suggests that there were gaps in rapid ART 
initiation for young adolescents when CD4-based eligibility criteria were in effect. These findings are in 
accordance with previous research that has highlighted a range of social and structural barriers to HIV 
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care and treatment for adolescents, whose needs may not be adequately met by service delivery 
strategies designed for younger children or adult HIV patients. [6, 7, 36, 37].  
  
The absolute effect of treatment eligibility expansions for young adolescents was greater under general 
Treat All policies than under earlier pediatric Treat All policies. This was noteworthy, given that large 
numbers of adult patients, newly-eligible under Treat All, could potentially strain HIV service provision, 
leading to the crowding out of vulnerable groups, such as young adolescents, for whom tailored 
interventions and services are recommended [11, 15, 38-40]. These results lend support for the 
supposition that general Treat All policies, with harmonized treatment recommendations for different 
population groups, are easier to implement in real-world treatment settings than prior policies targeting 
specific groups. Age-agnostic guidelines may help simplify the provision of HIV treatment in low-
resourced health systems in ways that lead to efficiency gains in service delivery [41, 42].  
 
Given the three-year interval between the pediatric Treat All expansions of 2013 and the general Treat 
All expansions of 2016, findings may also reflect temporal trends in provider preparedness, health 
system capacities to rapidly implement expanded treatment guidelines, and improved strategies for 
initiating patients on ART, despite decreases in donor funding for HIV during the period [43, 44].  
While immediate increases in rapid ART initiation among 10- to 14-year-olds were smaller following 
national adoptions of pediatric Treat All policies, the average annual rate of change in rapid ART 
initiation increased significantly following the adoption of these policies in 2013. Consistent with the 
smaller immediate effect observed at the Treat All adoption threshold, this may reflect a gradual roll-out 
or delayed implementation of the policy. In contrast, the lack of a statistically significant change in 
annual rates of rapid ART initiation following general Treat All policy adoptions in 2016 may be due to 
the high rates of rapid ART initiation achieved immediately after the policy (85.4%), with limited space 
for further increases above this level, as well as regression to the mean.  
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A concerning finding was the large decrease in pre-treatment CD4 measurement, as reflected by an 
increased proportion of young adolescents with no CD4 measures prior to treatment initiation. This 
finding is not unique to our study population [26, 45, 46], and reflects a larger trend of abandoning the 
use of CD4 monitoring altogether in sub-Saharan Africa, driven by combinations of cost and laboratory 
supply chain issues, as well as prioritization of viral load over CD4 testing [47-49]. Treat All policies have 
negated the need for CD4 to assess eligibility for treatment, and routine CD4 monitoring after ART 
initiation is generally not necessary in virally suppressed patients in settings with routine viral load 
testing [50, 51]. However, assessing pre-treatment CD4 remains important for identifying severely 
immunodeficient individuals who need enhanced clinical services, such as treatment of opportunistic 
infections [52-54] and for monitoring progress towards achieving the public health goals of HIV care and 
treatment scale-up [51].  
 
A strength of this analysis is the use of a regression discontinuity design with real-world service delivery 
data from diverse settings in seven sub-Saharan African countries that adopted Treat All policies at two 
points in time. This quasi-experimental design provides support for the causal interpretation of the 
association between expanded ART eligibility under Treat All and increases in rapid ART uptake among 
young adolescents newly enrolling into HIV care. The use of a data-driven Imbens-Kalyanaraman 
bandwidth [32] and sensitivity analyses with three other bandwidths enabled us to generate robust 
effect estimates with minimal risk of researcher bias.  
 
A limitation of our study is lack of complete data on treatment eligibility criteria for patients enrolling 
prior to national Treat All policy adoption (e.g., pre-treatment CD4 counts, WHO staging, and coinfection 
with TB). Such data would have allowed for the use of a “fuzzy” regression discontinuity design [29] to 
better reflect the probabilistic distribution of ART eligibility in the pre-Treat All sample. In addition, the 
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limited availability of data on patient characteristics beyond age, sex, and pre-treatment CD4 count 
restricted our ability to assess whether patients on each side of the regression discontinuity threshold 
were similar with respect to other pre-treatment covariates. We also lacked data on service delivery 
strategies, including tailored services for adolescents, and supply side constraints, such as drug 
stockouts, that may influence rapid ART initiation among young adolescents enrolling into care. 
Moreover, while we know the dates when Treat All policies were adopted in each country, lags in site-
level implementation likely varied across sites and countries included in this analysis [55]. Finally, the 
use of a 30-day rapid ART initiation window, intended to enable comparisons with this group’s prior 
work [27], limits the comparability of findings to WHO’s rapid ART initiation estimates defined by a 7-
day window after confirming HIV diagnosis.  
 
These limitations notwithstanding, our results suggest that expanded treatment eligibility under Treat 
All has benefited 10-to-14-year-olds by getting them onto treatment more rapidly following enrollment 
in care. As there are few age-disaggregated data related to the HIV care continuum for this age group, 
this study fills an important gap, indicating that an increasing share of young adolescents may be 
initiating ART rapidly under Treat All policies. While these results are encouraging, further research is 
needed on effective strategies for enrolling children with perinatally-acquired HIV in HIV care earlier and 
improving care retention and ART adherence among adolescent patients to support sustained viral 
suppression among this vulnerable population.  
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Figure 1 
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Figure 2 
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